Cargando…

Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma

This letter to the editor comments on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma

Detalles Bibliográficos
Autores principales:	Rizzo, Alessandro, Dalia Ricci, Angela, Brandi, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732236/ https://www.ncbi.nlm.nih.gov/pubmed/35993601 http://dx.doi.org/10.1093/oncolo/oyac168

Ejemplares similares

In Reply: Neoadjuvant TKI Study in Early- and Intermediate Stage Hepatocellular Carcinoma
por: Osanto, Susanne, et al.
Publicado: (2022)

Trans-Arterial Chemoembolization Plus Systemic Treatments for Hepatocellular Carcinoma: An Update
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Neoadjuvant Treatment with Angiogenesis‐Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study
por: Woei‐A‐Jin, F.J. Sherida H., et al.
Publicado: (2021)

Is post‐transplant chemotherapy feasible in liver transplantation for colorectal cancer liver metastases?
por: Brandi, Giovanni, et al.
Publicado: (2020)

Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2023)

Immune-Based Combination Therapies for Advanced Hepatocellular Carcinoma
por: Carloni, Riccardo, et al.
Publicado: (2023)

Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib
por: Joensuu, Heikki, et al.
Publicado: (2017)

Dovitinib enhances temozolomide efficacy in glioblastoma cells
por: Thanasupawat, Thatchawan, et al.
Publicado: (2017)

Dovitinib preferentially targets endothelial cells rather than cancer cells for the inhibition of hepatocellular carcinoma growth and metastasis
por: Chen, Zhi-Yuan, et al.
Publicado: (2012)

The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora’s box?
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

Immunotherapy in Biliary Tract Cancer: Worthy of a Second Look
por: Ricci, Angela Dalia, et al.
Publicado: (2020)

PD-L1, TMB, MSI, and Other Predictors of Response to Immune Checkpoint Inhibitors in Biliary Tract Cancer
por: Rizzo, Alessandro, et al.
Publicado: (2021)

Bayesian analysis supports the role of neoadjuvant chemoradiation followed by surgery for resectable locoregional esophageal cancer
por: Rizzo, Alessandro
Publicado: (2022)

Genomewide transcriptomic profiling identifies a gene signature for predicting recurrence in early‐stage hepatocellular carcinoma
por: Kakisaka, Tatsuhiko, et al.
Publicado: (2021)

Pilot study of dovitinib in patients with von Hippel-Lindau disease
por: Pilié, Patrick, et al.
Publicado: (2018)

Fibrolamellar hepatocellular carcinoma presenting with early recurrent thrombosis
por: Kundakcioglu, Hacer, et al.
Publicado: (2022)

Management of patients with intermediate stage hepatocellular carcinoma
por: Prince, David, et al.
Publicado: (2020)

Dovitinib induces mitotic defects and activates the G(2) DNA damage checkpoint
por: Man, Wing Yu, et al.
Publicado: (2014)

Intermediate stage hepatocellular carcinoma: a summary review
por: Elshaarawy, Omar, et al.
Publicado: (2019)

Is transarterial embolization plus two-stage hepatectomy the optimal strategy for the treatment of spontaneous rupture of hepatocellular carcinoma?
por: He, Tao, et al.
Publicado: (2023)

Buschke–Lowenstein tumor: An intermediate between condyloma acuminata and verrucous carcinoma
por: Singh, Yogindher, et al.
Publicado: (2022)

Octreotide and hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2007)

Prognostic Value of Postoperative Circulating Tumor DNA in Patients With Early- and Intermediate-Stage Hepatocellular Carcinoma
por: Ye, Ke, et al.
Publicado: (2022)

Tissue-infiltrating lymphocytes signature predicts survival in patients with early/intermediate stage hepatocellular carcinoma
por: Tian, Meng-Xin, et al.
Publicado: (2019)

Are FGFR and IDH1-2 alterations a positive prognostic factor in intrahepatic cholangiocarcinoma? An unresolved issue
por: Brandi, Giovanni, et al.
Publicado: (2023)

Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
por: Shivapurkar, Narayan, et al.
Publicado: (2017)

Induction of Neuroendocrine Differentiation in Prostate Cancer Cells by Dovitinib (TKI-258) and its Therapeutic Implications
por: Yadav, Shalini S., et al.
Publicado: (2017)

A mutation-specific, single-arm, phase 2 study of dovitinib in patients with advanced malignancies
por: Taylor, Matthew H., et al.
Publicado: (2020)

Adjuvant therapy in patients with rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy and radical resection in pathological stages I–III
por: Lino-Silva, Leonardo S., et al.
Publicado: (2020)

Neoadjuvant chemotherapy in locally advanced invasive lobular carcinoma: A limited institutional experience
por: Gogia, Ajay, et al.
Publicado: (2018)

Molecular Profile and Prognostic Value of BAP1 Mutations in Intrahepatic Cholangiocarcinoma: A Genomic Database Analysis
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Systemic Treatment for Metastatic Biliary Tract Cancer: State of the Art and a Glimpse to the Future
por: Rizzo, Alessandro, et al.
Publicado: (2022)

Bridging and downstaging with TACE in early and intermediate stage hepatocellular carcinoma: Predictors of receiving a liver transplant
por: Yin, Chao, et al.
Publicado: (2022)

Megestrol treatment in patients with hepatocellular carcinoma
por: Farinati, F, et al.
Publicado: (2001)

Drug-eluting beads in hepatocellular carcinoma
por: Abe, Hiroyuki, et al.
Publicado: (2017)

Hepatocellular carcinoma biomarkers, an imminent need
por: Zamora-León, S Pilar
Publicado: (2021)

Implications of pseudogenes for the prognosis of hepatocellular carcinoma
por: Liu, Zaoqu, et al.
Publicado: (2023)

New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_6tpldo0k6ts80hom4ed2famm23